Evidence map›Paper›PMID 42726417›Full record

ReviewNeuropsychology review2026

Cognitive Deficits and Neuropsychological Assessment in Non-Revascularized Moyamoya Disease Patients: a Systematic Review.

Serena Beretta, Irene Scala, Isabella Canavero, Giulia Marinoni, Carolina De Toma, Laura Gatti, Antonella Potenza, Tatiana Carrozzini, Gemma Gorla, Elisabetta Soldini and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neuropsychology review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Serena BerettaPostgraduate School of Neuropsychology, Università Cattolica del Sacro Cuore, Milan, Italy.
Irene ScalaCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy. irene.scala@istituto-besta.it.ORCID http://orcid.org/0000-0003-2370-840X
Isabella CanaveroCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Giulia MarinoniCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Carolina De TomaCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Laura GattiCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Antonella PotenzaCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Tatiana CarrozziniCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Gemma GorlaCerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Elisabetta SoldiniNeurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Sylvie PiacentiniNeuropshycological Unit, Department of Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Letizia ClementiNeurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Nicola Rifino *Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.
Anna Bersano *Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria 11, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Moyamoya Angiopathy (MMA) is a rare, progressive, steno-occlusive cerebrovascular disorder. The disease can be idiopathic (Moyamoya Disease, MMD) or associated with heritable or acquired conditions (i.e., Moyamoya Syndrome, MMS). Among clinical symptoms of MMA, cognitive aspects are acknowledged but not well-characterized, and their proper neuropsychological assessment has never been standardized. We conducted a systematic review to investigate the characteristics of cognitive deficits in non-revascularized adults MMD patients, as well as the main neuropsychological tests used for their evaluation. The literature search was performed by two independent reviewers across three different databases, including PubMed, EMBASE, and Scopus. Quality assessment was independently performed by two reviewers through the Johanna Briggs Institute critical appraisal tools. Data on sample size, patients' demographics, age at diagnosis, clinical and radiological characteristics of MMD, administered neuropsychological tests, prevalence of cognitive impairment (CI), and altered cognitive domains were extracted. The literature search allowed the inclusion of 12 papers, confirming the limited literature on this topic. The prevalence of CI ranged from 23 to 92% across studies. Executive functions, especially processing speed and cognitive flexibility, followed by memory skills appeared to be the most affected cognitive domains. Conversely, other cognitive functions have been less investigated. The most commonly used neuropsychological tests were the Trail Making Test, the Digit Span test, and Verbal Fluency. Despite growing awareness and knowledge of cognitive aspects in patients with MMD, inconsistency remains in identifying specific neuropsychological profiles, and no standardized assessment protocol has yet been established.

Indexed as

Cognitive deficitCognitive impairmentMoyamoya angiopathyMoyamoya diseaseNeuropsychological assessment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.